Show simple item record

dc.contributor.authorRad, Amir
dc.contributor.authorSørbye, Sveinung
dc.contributor.authorBrenn, Tormod
dc.contributor.authorTiwari, Sweta
dc.contributor.authorLøchen, Maja-Lisa
dc.contributor.authorSkjeldestad, Finn Egil
dc.date.accessioned2023-09-04T10:21:10Z
dc.date.available2023-09-04T10:21:10Z
dc.date.issued2023-02-25
dc.description.abstractBackground: A specific, cost-effective triage test for minor cytological abnormalities is essential for cervical cancer screening among younger women to reduce overmanagement and unnecessary healthcare utilization. We compared the triage performance of one 13-type human papillomavirus (HPV) DNA test and one 5-type HPV mRNA test. Methods: We included 4115 women aged 25–33 years with a screening result of atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) recorded in the Norwegian Cancer Registry during 2005–2010. According to Norwegian guidelines, these women went to triage (HPV testing and repeat cytology: 2556 were tested with the Hybrid Capture 2 HPV DNA test, which detects the HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68; and 1559 were tested with the PreTect HPV-Proofer HPV mRNA test, which detects HPV types 16, 18, 31, 33, and 45). Women were followed through December 2013. Results: HPV positivity rates at triage were 52.8% and 23.3% among DNAand mRNA-tested women (p < 0.001), respectively. Referral rates for colposcopy and biopsy and repeat testing (HPV + cytology) after triage were significantly higher among DNA-tested (24.9% and 27.9%) compared to mRNA-tested women (18.3% and 5.1%), as were cervical intraepithelial neoplasia grade 3 or worse (CIN3+) detection rates (13.1% vs. 8.3%; p < 0.001). Ten cancer cases were diagnosed during follow-up; eight were in DNA-tested women. Conclusion: We observed significantly higher referral rates and CIN3+ detection rates in young women with ASC-US/LSIL when the HPV DNA test was used at triage. The mRNA test was as functional in cancer prevention, with considerably less healthcare utilization.en_US
dc.identifier.citationRad, Sørbye, Brenn, Tiwari, Løchen, Skjeldestad. 13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Up. International Journal of Environmental Research and Public Health (IJERPH). 2023;20(5)en_US
dc.identifier.cristinIDFRIDAID 2155588
dc.identifier.doi10.3390/ijerph20054119
dc.identifier.issn1661-7827
dc.identifier.issn1660-4601
dc.identifier.urihttps://hdl.handle.net/10037/30664
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.relation.ispartofRad, A. (2023). HPV mRNA and HPV DNA Tests in Cervical Cancer Screening. (Doctoral thesis). <a href=https://hdl.handle.net/10037/31583>https://hdl.handle.net/10037/31583</a>
dc.relation.journalInternational Journal of Environmental Research and Public Health (IJERPH)
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.title13-Type HPV DNA Test versus 5-Type HPV mRNA Test in Triage of Women Aged 25–33 Years with Minor Cytological Abnormalities–6 Years of Follow-Upen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)